Radiotherapy for regionally localized hormone refractory prostate cancer

International Journal of Radiation Oncology, Biology, Physics

Volumn 33, Issue 4, 1995, Pages 907-912

  Lankford, Scott P ^a   Pollack, Alan ^a   Zagars, Gunar K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Androgen ablation; Hormone refractory; Prostate cancer; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FOLLOW UP; HORMONAL REGULATION; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME; TUMOR LOCALIZATION; URINARY TRACT OBSTRUCTION;

ACID PHOSPHATASE; ADENOCARCINOMA; ADULT; AGED; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMAN; MALE; MIDDLE AGE; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 0028786117     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(95)02005-0     Document Type: Article

References (6)

1. Radiotherapy and androgen ablation for clinically localized high risk prostate cancer
2. Sodium thymolphthalein monophosphate: A new acid phosphatase substrate with greater specificity for the prostate enzyme in serum
3. Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation
4. Early androgen ablation for stage D1 (N1–N3, M0) prostate cancer: Prognostic variables and outcome
5. Stage C adenocarcinoma of the prostate: An analysis of 551 patients treated with external beam radiotherapy